Gossamer Bio shares surge after FDA filing update; cash concerns and dilution still loom

NEW YORK, July 27, 2026, 3:02 p.m. EDT. Gossamer Bio shares rose sharply after the company outlined its FDA filing strategy, but lingering questions over cash reserves and potential shareholder dilution persist.

27 July 2026

SELLAS Life Sciences (NASDAQ:SLS) drops as new share count suggests $2.14 billion market cap

Shares of SELLAS Life Sciences Group, Inc. slid 3.9% on Monday following an 8.3% decline on Friday. The stock reached a low of $9.60 before rebounding to $10.88.

27 July 2026

Biotechnology·NASDAQ:SLS·Pharmaceuticals·Stock Market

Capricor Therapeutics (NASDAQ:CAPR) shares tumble 67% after FDA raises concerns over Deramiocel data

Shares of Capricor Therapeutics, Inc. fell by nearly two-thirds on Monday after U.S. regulators raised concerns over the efficacy data for deramiocel, the company’s treatment aimed at Duchenne muscular dystrophy.

27 July 2026

Biotechnology·Pharmaceuticals·Stock Market

CSL Limited (ASX:CSL) Stock Ends Week Down 7.4% as HEMGENIX Progress Faces Scale Test

CSL Limited enters Monday after five straight losses erased 7.4% from its share price, Friday-to-Friday. Shares closed Friday at A$114.22, down 1.3% on the day. The ASX cash market was closed at publication; pre-open begins at 07:00 AEST.

26 July 2026

ASX:CSL·Biotechnology·Pharmaceuticals·Stock Market

Viking Therapeutics (NASDAQ:VKTX) Stock in Focus Ahead of Cash-Burn Scrutiny, Earnings Set for July 29

Viking heads into earnings week as its shares face downward pressure. The stock dropped 6.2% last week, with a 1.7% decrease on Friday.

26 July 2026

Biotechnology·Earnings Reports·NASDAQ:VKTX·Pharmaceuticals·Stock Market

SELLAS Life Sciences shares drop 14% amid REGAL delay, challenging $2.2 billion valuation

NEW YORK, July 26, 2026, 14:22 EDT — With U.S. markets now closed, SELLAS Life Sciences stock ended down 14% as investors grew cautious waiting for updates on the REGAL program, testing the company's $2.2 billion market value.

26 July 2026

Biotechnology·NASDAQ:SLS·Pharmaceuticals·Stock Market

Teva Q2 Earnings Preview: Emalex Impact Offsets Branded-Drug Gains

Teva Pharmaceutical Industries is set to release its second-quarter results on Wednesday, featuring an atypical split in earnings. Underlying business performance could strengthen, but reported non-GAAP earnings are expected to approach zero.

26 July 2026

Earnings Reports·NYSE:TEVA·Pharmaceuticals·Stock Market

Pfizer (NYSE:PFE) shares down 1.9% on Friday; dividend seen as main driver

Pfizer ended the session $0.47 under Thursday’s unadjusted close. Of that difference, the planned $0.43 dividend accounted for 91%.

25 July 2026

Dividends·NYSE:PFE·Pharmaceuticals·Stock Market

GSK confronts £3.6 billion sales shortfall ahead of strategy update on Tuesday

GSK plc will present its strategy update on Tuesday as it faces a £3.63 billion shortfall in sales projections. Consensus forecasts compiled by the company estimate 2031 revenue at £36.37 billion, while management’s objective is above £40 billion.

25 July 2026

Earnings·LON:GSK·Pharmaceuticals·Stock Market

Outlook Therapeutics (NASDAQ:OTLK) suspended post-Lytenava approval, with funding under pressure from looming warrants

Outlook Therapeutics, Inc. received U.S. clearance for Lytenava on Friday. Trading in its shares was paused following the news.

24 July 2026

Biotechnology·NASDAQ:OTLK·Pharmaceuticals·Stock Market

Peptide catalyst lift for Hims & Hers (NYSE:HIMS) limited by FDA review timetable

Hims & Hers Health finished up 3.4% at $32.74 on Thursday. Four unapproved peptides received backing from U.S. advisers for pharmacy compounding, opening the door to a potential $440 million sales opportunity in 2027.

24 July 2026

NYSE:HIMS·Pharmaceuticals·Stock Market

TrumpRx’s 800-drug increase intensifies tariff threat facing generic drug manufacturers

Shares of U.S. generic drugmakers declined on Wednesday after President Donald Trump announced a schedule for new tariffs. Generic drugs brought into the U.S. could see tariffs reaching 200% starting in 2029. U.S. cash markets were shut.

23 July 2026

NASDAQ:GILD·NASDAQ:VTRS·NYSE:PFE·NYSE:TEVA·Pharmaceuticals·SWX:SDZ

InMed Pharmaceuticals (NASDAQ:INM) climbs after $200 million Mentari infusion strengthens merger funding calculations

Shares of InMed Pharmaceuticals Inc. climbed 21% to $1.87 during late-morning trading on the Nasdaq. Mentari Therapeutics, which is merging with InMed, revealed a $200 million private placement.

22 July 2026

Biotechnology·NASDAQ:INM·Pharmaceuticals·Stock Market

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) leaves Nasdaq after cash reserves reduce deal multiple

Catalyst shares were removed from trading on Wednesday after Angelini Pharma finalised its $4.1 billion all-cash acquisition. Investors were paid $31.50 per share. Nasdaq halted trading in Catalyst following completion of the deal.

22 July 2026

NASDAQ:CPRX·Pharmaceuticals·Stock Market

China Pharma (NYSEAMERICAN:CPHI) surges 790%, raising patent-share block’s notional value to $202 million

China Pharma Holdings, Inc. stated there was no significant development to account for Tuesday’s 790% jump. The sharp move also shifted the value of two February patent deals.

22 July 2026

NYSEAMERICAN:CPHI·Pharmaceuticals·Stock Market

Catalyst Pharmaceuticals (NASDAQ:CPRX) departs Nasdaq as merger spread narrows to one cent

U.S. markets operated as usual on Tuesday, though Catalyst shares did not trade. Nasdaq halted trading activity after the company was acquired by Angelini Pharma.

21 July 2026

NASDAQ:CPRX·NYSE:BX·Pharmaceuticals·Stock Market

Telix Pharmaceuticals trails ASX 200 by 8.3 points; Japan remains beyond guidance

Telix Pharmaceuticals Ltd opened Monday trading at A$14.91, its last available price. Shares dropped 4.48% on Friday. Australia's cash market was active, though Google Finance continued to display Friday’s data.

20 July 2026

ASX News·ASX:TLX·NASDAQ:TLX·Pharmaceuticals·Stock Market

Viking Therapeutics (NASDAQ:VKTX) stock maintains Phase 3 outlook despite 4.6% fall over the week

Viking Therapeutics, Inc. declined by 4.6% over the past week. Nonetheless, its initial cash-adjusted valuation remained 86% higher than that of Structure Therapeutics Inc..

18 July 2026

NASDAQ:GPCR·NASDAQ:VKTX·Pharmaceuticals

Iovance Biotherapeutics (NASDAQ:IOVA) shares jump 18% as Amtagvi sales test approaches

Iovance Biotherapeutics, Inc. gained approximately $344 million in equity value last week, representing 95.5% of its $360 million midpoint for full-year revenue guidance. U.S. markets were closed on Saturday. The company's shares ended Friday at $5.00.

18 July 2026

NASDAQ:IOVA·Pharmaceuticals·Stock Market

Iovance (NASDAQ:IOVA) gains after $89.7 million stock sale

Iovance shares surge as attention shifts to Amtagvi’s second-half sales target

Iovance finished Thursday at $4.66, gaining 10.2% from July 10. Nasdaq’s regular session had ended at the dateline, while premarket trading remained open.

17 July 2026

NASDAQ:IOVA·Pharmaceuticals·Stock Market

Previous 1 … 4 5 6 7 8 … 49 Next

SELLAS Life Sciences (NASDAQ:SLS) drops as new share count suggests $2.14 billion market cap

Capricor Therapeutics (NASDAQ:CAPR) shares tumble 67% after FDA raises concerns over Deramiocel data

CSL Limited (ASX:CSL) Stock Ends Week Down 7.4% as HEMGENIX Progress Faces Scale Test

Viking Therapeutics (NASDAQ:VKTX) Stock in Focus Ahead of Cash-Burn Scrutiny, Earnings Set for July 29

SELLAS Life Sciences shares drop 14% amid REGAL delay, challenging $2.2 billion valuation

Teva Q2 Earnings Preview: Emalex Impact Offsets Branded-Drug Gains

Pfizer (NYSE:PFE) shares down 1.9% on Friday; dividend seen as main driver

GSK confronts £3.6 billion sales shortfall ahead of strategy update on Tuesday

Outlook Therapeutics (NASDAQ:OTLK) suspended post-Lytenava approval, with funding under pressure from looming warrants

Peptide catalyst lift for Hims & Hers (NYSE:HIMS) limited by FDA review timetable

TrumpRx’s 800-drug increase intensifies tariff threat facing generic drug manufacturers

InMed Pharmaceuticals (NASDAQ:INM) climbs after $200 million Mentari infusion strengthens merger funding calculations

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) leaves Nasdaq after cash reserves reduce deal multiple

China Pharma (NYSEAMERICAN:CPHI) surges 790%, raising patent-share block’s notional value to $202 million

Catalyst Pharmaceuticals (NASDAQ:CPRX) departs Nasdaq as merger spread narrows to one cent

Telix Pharmaceuticals trails ASX 200 by 8.3 points; Japan remains beyond guidance

Viking Therapeutics (NASDAQ:VKTX) stock maintains Phase 3 outlook despite 4.6% fall over the week

Iovance Biotherapeutics (NASDAQ:IOVA) shares jump 18% as Amtagvi sales test approaches

Iovance shares surge as attention shifts to Amtagvi’s second-half sales target

TechStock² Updates

SCHD up 24%, yield trails Treasuries by 1.6 points

Nu Holdings Falls 1.2% Before Market Open as P/E Multiple Outpaces Bank Rivals

Oracle Stock Falls 3.1% as Layoff Report Highlights $55.7 Billion Capital Bill

Oklo Shares Dip 1.2% Before Market Open as 23 Million-Share Offering Overshadows Insider Selling

Oil Steady Over $92 While Nasdaq Futures Drop 1%

Take-Two shares drop 6.7%, $2.9 billion market value lost prior to GTA VI launch

Ather Energy shares climb to all-time high, rising 17% above Hero MotoCorp block price

Recovered Bitcoin Wallet Is Worth $4.76 Million as Custody Risk Dwarfs Price Swing

SpaceX Stock Slips 1.2% Premarket as $300 Target Faces Profit Test

CNH Stock Slips 0.5% Premarket as 7.2x Volume Tests Baird’s $15 Recovery Bet

Investment Disclaimer